Patents Examined by Sheela Huff
  • Patent number: 7217796
    Abstract: The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.
    Type: Grant
    Filed: May 22, 2003
    Date of Patent: May 15, 2007
    Assignee: Schering Corporation
    Inventors: Yan Wang, Robert Greenberg, Leonard Presta, Jonathan A. Pachter, Judith Hailey, Peter Brams, Denise Williams, Mohan Srinivasan, Diane Feingersh
  • Patent number: 7217795
    Abstract: A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed.
    Type: Grant
    Filed: November 19, 2002
    Date of Patent: May 15, 2007
    Assignees: Myriad Genetics, Inc., Board of Regents, The University of Texas Systems
    Inventors: Peter Steck, Mark A. Pershouse, Samar A. Jasser, Alfred W. K. Yung, Sean V. Tavtigian
  • Patent number: 7208583
    Abstract: An isolated nucleic acid molecule encoding a human DNA repair enzyme, MED1, is disclosed. Like other mismatch repair genes which are mutated in certain cancers, MED1, encoding nucleic acids, proteins and antibodies thereto may be used to advantage in genetic or cancer screening assays. MED1, which recognizes and cleaves DNA, may also be used for the diagnostic detection of mutations and genetic variants.
    Type: Grant
    Filed: July 29, 2003
    Date of Patent: April 24, 2007
    Assignee: Fox Chase Cancer Center
    Inventor: Alfonso Bellacosa
  • Patent number: 7202343
    Abstract: Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucelotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Grant
    Filed: August 19, 2003
    Date of Patent: April 10, 2007
    Assignee: Abgenix, Inc.
    Inventors: Jean M. Gudas, Mary Haak-Frendscho, Orit Foord, Meina L. Liang, Kiran Ahluwalia, Sunil Bhakta
  • Patent number: 7202346
    Abstract: The present invention relates to antibodies, antibody fragments, conjugates of antibodies and antibody fragments with cytotoxic agents, and hybridomas producing the antibodies and antibody fragments, where the antibodies and antibody fragments recognize extracellular epitopes of plasma membrane proteins that are not released into the extracellular fluid, and to methods for the detection, monitoring and treatment of malignancies such as breast cancer and ovarian cancer using the antibodies, antibody fragments and conjugates.
    Type: Grant
    Filed: July 3, 2003
    Date of Patent: April 10, 2007
    Assignee: Immunogen Inc.
    Inventors: Gillian Payne, Thomas Chittenden, Viktor Goldmakher, Philip Chun, Kristin Sneider-Mulready, Carol A. Vater
  • Patent number: 7169901
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Grant
    Filed: September 3, 2002
    Date of Patent: January 30, 2007
    Assignee: Genentech, Inc.
    Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-yee Chen
  • Patent number: 7132109
    Abstract: The present invention provides for a method of using heat shock proteins (HSPs) to amplify the immune response initiated by a vaccine. HSPs can be introduced into a subject before, concurrently, or after the administration of a vaccine. The HSPs can also be used to activate antigen presenting cells which are then introduced into a subject in conjunction with a vaccine. The HSPs used in the methods of the invention can be unbound or can be covalently or noncovalently bound to a peptide that is unrelated to the vaccine. The subject is preferably mammalian, and most preferably human. It is shown by way of example herein that HSPs induces secretion of cytokines and surface expression of antigen-presenting and co-stimulatory molecules. The invention also encompasses methods of treatment and prevention of cancer and infectious diseases in a subject.
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: November 7, 2006
    Assignee: University of Connecticut Health Center
    Inventor: Pramod K. Srivastava
  • Patent number: 7108844
    Abstract: The invention concerns the use of stabilized oligonucleotides comprising at least an octamer motif of the type: 5?-purine-purine-CG-pyrimidine-pyrimidine-X1X2-3? wherein the pair X1-X2- is AT, AA, CT or TT, for preparing a medicine with antitumor activity.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: September 19, 2006
    Assignees: Assistance Publique-Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale
    Inventor: Antoine F. Carpentier
  • Patent number: 7105649
    Abstract: The invention provides, for example, a gene comprising a polynucleotide coding for the polypeptide having the amino acid sequence shown in SEQ ID NO:3. The gene shows amplification in the 9p23-24 region, has a PX domain and PHD finger motifs, plays an important role in cell growth and differentiation, and in tumorigenesis, and is useful in elucidating the pathology of various diseases caused by a protein involved in cell differentiation in malignant tumor or the like, and in the diagnosis and treatment of such diseases.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: September 12, 2006
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Inazawa Johji, Imoto Issei
  • Patent number: 7087409
    Abstract: A humanized murine antibody is provided. The amino acid sequences of a light chain complementarity determining region from a mouse antibody are grafted onto a human light chain, and a heavy chain complementarity determining region from a mouse antibody are grafted onto a human antibody heavy chain to produce libraries from which a humanized murine antibody having the desired specificity is selected.
    Type: Grant
    Filed: February 19, 2002
    Date of Patent: August 8, 2006
    Assignee: The Scripps Research Institute
    Inventors: Carlos F. Barbas, III, Christoph Rader
  • Patent number: 7084239
    Abstract: The present invention discloses the identification, isolation and cloning of a gene encoding a novel cancer antigen NY ESO-1CAG-3 and peptides thereof derived from various open reading frames from the NY ESO-1 gene. The novel cancer antigen and peptides are recognized by cytotoxic T lymphocytes in an HLA restricted manner. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.
    Type: Grant
    Filed: September 21, 1998
    Date of Patent: August 1, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Rong Fu Wang, Steven Rosenberg
  • Patent number: 7052832
    Abstract: The present invention relates to methods of identifying the susceptibility of cells to reovirus infection by measuring constitutive ras-MAP signaling. The invention also pertains to methods using reovirus for the treatment of cellular proliferative disorders, and particularly cellular proliferative disorders wherein the proliferating cells exhibit constitutive MAPK phosphorylation, in mammals. In particular, the methods provide for reovirus treatment of mammals to treat proliferative disorders which include breast tumors, a subset of tumors in which mutation of the ras gene is not believed to play a significant role.
    Type: Grant
    Filed: November 6, 2001
    Date of Patent: May 30, 2006
    Assignee: Oncolytics Biotech Inc.
    Inventor: Matthew C. Coffey
  • Patent number: 6818744
    Abstract: This invention relates to a new protein called RB18A for “Recognized By PAb18O1 moAntibody”, which is a p53 regulatory protein, to the nucleotide sequence encoding said protein, and to the diagnostic and therapeutic applications thereof, in particular for the diagnosis, prevention or treatment of neoplasia.
    Type: Grant
    Filed: August 14, 2000
    Date of Patent: November 16, 2004
    Inventor: Raymond Frade
  • Patent number: 6790445
    Abstract: Novel combination of preservatives (methyl and propyl parabens, benzyl alcohol, and 2-phenoxyethanol) were found to pass antimicrobial testing according to USP, BP, and EP. The new preservatives were put into vaccines using L-histidine as a buffer to keep pH at 7.0. HPLC methods were developed to analyze these preservatives and their degradation products.
    Type: Grant
    Filed: February 6, 1998
    Date of Patent: September 14, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Assunta S. Ng, Ralph J. Mancinelli, John P. Hennessey
  • Patent number: 6774223
    Abstract: The invention relates to CSG polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: August 10, 2004
    Assignee: diaDexus, Inc.
    Inventors: Roberto A. Macina, Rajeswari Pillai
  • Patent number: 6764995
    Abstract: The present invention provides anti-angiogenic compositions, and more particularly provides endostatin protein fragments. The compositions of the present invention may be used for the treatment of angiogenesis-dependent diseases such as cancer.
    Type: Grant
    Filed: September 23, 1999
    Date of Patent: July 20, 2004
    Assignee: The Children's Medical Center Corporation
    Inventors: Michael S. O'Reilly, M. Judah Folkman
  • Patent number: 6740637
    Abstract: Conjugates of chlorophyll (Chl) and bacteriochlorophyll (Bchl) derivatives with amino acids, peptides and proteins are provided by the invention. The amino acid, peptide or protein residue is linked to the 17-propionic acid group of a Chl or Bchl residue directly or through a chain. The conjugates are for use as photosensitizers in photodynamic therapy and in diagnostics of tumors. Conjugation with cell-specific ligands, such as hormones, growth factors or tumor-specific antibodies, will target the Chl or Bchl moiety to the tumor site. Thus, conjugates with melanocyte stimulating hormones are suitable for photodynamic therapy of melanoma tumors.
    Type: Grant
    Filed: July 13, 2000
    Date of Patent: May 25, 2004
    Assignee: Yeda Research And Development Co.
    Inventors: Avigdor Scherz, Yoram Salomon, Leszek Fiedor
  • Patent number: 6734168
    Abstract: The present invention provides for a purified endothelial monocyte activating polypeptide II, wherein the polypeptide has an apparent molecular weight of about 20,000 Daltons. The present invention also provides for an effector cell activating protein comprising a polypeptide having an amino acid sequence wherein at least four amino acid residues are the same as RIGRTVT and are in the same relative positions. The invention also provides for a DNA which encodes the effector cell activating protein. The invention also provides for methods of inducing inflammation in a subject and methods of treating tumors in a subject. The invention also provides for a pharmaceutical composition which comprises the endothelial monocyte activating polypeptide II and a carrier.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: May 11, 2004
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: David M. Stern, Matthias Clauss, Janet Kao, Mark Kayton, Steven K. Libutti
  • Patent number: 6716966
    Abstract: The invention provides therapeutic compositions comprising binding agents that specifically bind to tumor-associated MUC-1 and reduce, reverse or prevent their effects in cancer. More particularly, the invention provides therapeutic compositions that comprise a binding agent that can specifically bind to an epitope that comprises both peptide and carbohydrate on such tumor-associated MUC-1. The invention further provides methods for the use of such therapeutic compositions in the treatment of cancer.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: April 6, 2004
    Assignee: AltaRex Corp.
    Inventor: Ragupathy Madiyalakan
  • Patent number: 6703206
    Abstract: An immunological assay and kit for colon cancer screening is disclosed. Fecal glycoproteins are extracted from individual samples such that immunogenicity is maintained. The purified fecal glycoproteins are reacted with antibodies to Colon and Ovarian Tumor Antigen (COTA). The mucin antigen COTA is specifically present in colorectal cancer tissue and not in normal colons. The amount of COTA in the fecal sample is determined and used to indicate the presence of colon cancer.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: March 9, 2004
    Assignee: Loma Linda University Adventist Health Sciences Center
    Inventors: Keshab D. Pant, John D. McCracken, Omar Fagoaga, Wayne Kelln, Sandra Nehlsen-Cannarella